GC Genome Corporation (KOSDAQ:340450)
South Korea flag South Korea · Delayed Price · Currency is KRW
8,860.00
-240.00 (-2.64%)
At close: Feb 6, 2026

GC Genome Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
36,4876,5283,63713,63710,7439,404
Short-Term Investments
5,000-5,0004,00015,00020,000
Cash & Short-Term Investments
41,4876,5288,63717,63725,74329,404
Cash Growth
380.35%-24.42%-51.03%-31.49%-12.45%624.53%
Accounts Receivable
9,0315,4394,3074,2213,7021,604
Other Receivables
51.5712.9465.78325.427122.76
Receivables
9,0835,4524,3734,5463,7731,627
Inventory
2,0751,2191,1521,200598.2-
Prepaid Expenses
369.38371.57292.15697.09126.16384.8
Other Current Assets
78.7293.3396.2940.3730.690
Total Current Assets
53,09213,66314,55024,12030,27131,416
Property, Plant & Equipment
13,12214,91818,75918,0948,2936,642
Long-Term Investments
14,5297,8236,1033,2311,6481,928
Other Intangible Assets
508.22526.09533.37577.52617.6608.61
Long-Term Accounts Receivable
00-000-
Long-Term Deferred Tax Assets
928.11634.11680.04163.81-55.9
Other Long-Term Assets
3,2983,0582,1942,7091,6011,197
Total Assets
85,47740,62242,81948,89642,43141,848
Accounts Payable
1,556-851.581,3111,293-
Accrued Expenses
1,471109.91840.061,8301,1851,234
Short-Term Debt
--6,556---
Current Portion of Leases
838.87792.17802.31997.42685.06351.85
Current Income Taxes Payable
-----30.98
Current Unearned Revenue
1,6541,503941.61,2181,065434.33
Other Current Liabilities
675.22794.572,9865,036485.16434.69
Total Current Liabilities
6,1953,19912,97810,3934,7142,485
Long-Term Debt
---5,81912,91311,462
Long-Term Leases
3,3843,8784,3983,787508.18551.67
Pension & Post-Retirement Benefits
239.58----51.44
Long-Term Deferred Tax Liabilities
----9-
Other Long-Term Liabilities
483.15465.2395.842,3125,3208,645
Total Liabilities
10,3027,54317,77222,31123,46423,196
Common Stock
11,8259,7789,0679,0678,0008,000
Additional Paid-In Capital
68,25529,89021,03621,01010,47510,475
Retained Earnings
-3,623-5,281-3,964-3,244491.96-6.54
Comprehensive Income & Other
-1,282-1,307-1,091-247.95-184.08
Shareholders' Equity
75,17533,08025,04826,58518,96718,652
Total Liabilities & Equity
85,47740,62242,81948,89642,43141,848
Total Debt
4,2234,67011,75710,60414,10612,365
Net Cash (Debt)
37,2641,857-3,1207,03311,63617,039
Net Cash Growth
----39.56%-31.71%1449.35%
Net Cash Per Share
1802.77101.96-170.15435.45727.46955.99
Filing Date Shares Outstanding
23.6518.2218.3416.151617.82
Total Common Shares Outstanding
23.6518.2218.3416.151617.82
Working Capital
46,89710,4641,57213,72825,55728,930
Book Value Per Share
3178.561815.961366.011646.071185.741046.53
Tangible Book Value
74,66732,55424,51426,00818,34918,044
Tangible Book Value Per Share
3157.071787.081336.921610.311147.131012.38
Buildings
4,3817,1427,7276,8101,111609
Machinery
4,55112,81413,05511,3329,8007,550
Construction In Progress
---77.14--
Source: S&P Global Market Intelligence. Standard template. Financial Sources.